# Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study

> **NCT07729917** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhejiang University** · enrollment: 240 (estimated)

## Conditions studied

- Bile Duct Carcinoma
- Cholangiocarcinoma

## Interventions

- **DRUG:** FGFR Inhibitor
- **DRUG:** IDH1 mutation inhibitor
- **DRUG:** KRAS mutation inhibitor
- **DRUG:** NTRK mutation inhibitor
- **DRUG:** BRAF V600E mutation inhibitor
- **DRUG:** BRCA 1/2 mutation inhibitor
- **DRUG:** HER2 target therapy
- **DRUG:** Immune Checkpoint Inhibitors
- **DEVICE:** Chemotherapy: GP/GEMOX

## Key facts

- **NCT ID:** NCT07729917
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-10
- **Primary completion:** 2028-08-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07729917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07729917, "Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07729917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*